Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs
Eli Lilly became the first U.S. health care company to reach a $1 trillion market value on November 21, 2025. The company now stands with giants such as Apple, Amazon, and Nvidia. Shares touched 1,061.17 in early trading and closed at 1,059.70, up 2%. The price increase kept the company above the trillion-dollar threshold.
CNBC reported that Berkshire Hathaway was the only other non-tech firm in the U.S. to cross the same milestone. Eli Lilly reached the mark after a strong year in which its stock gained 35%. The growth followed a deal with the Trump administration to sell its weight-loss drug Zepbound at a lower price. The drug is available on the new direct-to-consumer site TrumpRx. The agreement also allows the company to sell Zepbound and its diabetes drug Mounjaro to Medicare at lower prices.
Industry experts expect the lower prices to grow the market. Many patients could not afford these drugs before. Brad Stewart of BDO told Investor’s Business Daily that usage in weight-loss treatment remains low. He said diabetes penetration is higher but still leaves room for growth. He expects revenue to expand as more people start treatment.
Eli Lilly stock shows strong performance indicators. It holds a 99 Composite Rating on IBD Digital. This rating measures fundamentals and technicals against other U.S. stocks. Lilly ranks ahead of 99% of them. Shares recently broke past the previous record high of 972.53 set in August 2024. The stock now trades about 8% above that benchmark.
The company also holds a 93 Relative Strength Rating. This compares the last 12 months of performance against the whole market. Eli Lilly has an EPS Rating of 98, placing it among the top 2% of U.S. companies in profit growth.
#EliLilly #StockMarket #PharmaNews #TrillionDollarCompany #Investment